imo the shares issued were to pay off WOLV's own
imo the shares issued were to pay off WOLV's own preexisting obligations -the 10Q notes a working capital deficit of 362k, an increase from 267k- detail in filings implies the increase is due to costs
to Bruce and texada- see former posts of mine which would include possibly attorney and accounting etc fees re the deal since i havent seen those specific fees noted anywhere
to set up this deal-which might be apportioned differently but wasnt- but the 267k was certainly totally WOLV's preexisting debt-and the 10Q forecast they would have to do this pp etc and pay off creditors so WOLV would have totally clean financials going into the closing of the deal w Enigma-which makes sense-they want to get rid of the baggage of pre-existing WOLV debt
shares issued to ca 24 people total for preexisting debt to those people, plus the pp -
not part of the 300 million shares to ENIGMA which are conditioned on Enigma raising 2.5 million -w the deal set to close ca june 20 if i remember-would have to look when i have more time but that may imply Enigma has to raise the 2.5 m by time of closing of the deal ca june 20 since ''The Agreement is subject to Enigma completing a financing of $2,500,000..'' would have to look when have more time
remember some filing forecast up to 150 million shares could be issued by WOLV to pay off this pre-existing WOLV debt etc
from 10Q
Subsequent Event
On April 14, 2015, the Company entered into a Share Exchange and Royalty Agreement pursuant to which the Company will acquire 25% interest in the process technology and cyber security company ENIGMAMobil Inc. (“Enigma”) for the purchase price of $3,000,000, to be paid in shares of common stock of the Company. The Company will also receive 25% royalty of all gross revenue received by Enigma from the sale of licenses of ENIGMAMobil™ mobile security app. The Company agreed to issue a finder’s fee consisting of 30,000,000 shares of common stock of the Company (the “Finder’s Shares”).The Agreement is subject to Enigma completing a financing of $2,500,000 and the Company increasing its authorized capital of common stock to allow for the issuance of the Shares and Finder’s Shares
Wolverine Technologies Corp. (WOLV) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Nokia Corporation's Latest Management Transactions Nokia Corporation has recently announced significant management transactions that emphasize its ongoing operational strategies and technological innovations. Today, we dive into the details of one particular transaction involving a key manager in the company. Transaction Details This transaction notification is made under...
Continue Reading
Huawei's New AI WAN Solution Unveiled At the Mobile World Congress in Barcelona, Huawei introduced the AI WAN Solution, a groundbreaking development designed to revolutionize networking. Leon Wang, the President of Huawei's Data Communication Product Line, emphasized the importance of merging AI with network infrastructures. This new solution aims to enhance IP networks...
Continue Reading
Transforming Business Dreams with Innovative Software Solutions FM, a pioneer in custom software development augmented by AI technology, is revolutionizing how businesses approach growth and scalability. In a rapidly changing landscape, where adaptability is key, FM’s approach enables organizations to leverage generative software solutions that are more accessible than...
Continue Reading
Community Investment and Support for Caesars Palace Times Square During a recent public hearing, community support was overwhelmingly evident for the Caesars Palace Times Square project. Local residents, small business owners, union workers, and city leaders gathered to express their enthusiasm for a project that promises to generate significant economic growth and create...
Continue Reading
Groundbreaking News from Aquestive Therapeutics Aquestive Therapeutics, Inc. (NASDAQ: AQST), a forward-thinking pharmaceutical company dedicated to enhancing patient care through innovative drug delivery solutions, has officially received word from the U.S. Food and Drug Administration (FDA) that no advisory committee meeting will be required for the New Drug Application...
Continue Reading